[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"survival-rate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:survival-rate":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100593804","phase-1-clinical-outcomes-of-early-kasai-surgery-with-umbilical-cord-mscs-in-biliary-atresia-100593804",false,"NCT07011199","Clinical Outcomes of Early Kasai Surgery With Umbilical Cord MSCs in Biliary Atresia","Evaluation of Clinical Outcomes in Biliary Atresia Patients Undergoing Kasai Surgery Before 90 Days of Age With Umbilical Cord-Derived Mesenchymal Stem Cell Therapy","Inclusion Criteria:\n\n* Infants diagnosed with biliary atresia confirmed by intraoperative findings.\n* Underwent Kasai portoenterostomy at an age less than 90 days.\n* Parents or legal guardians have provided informed consent to participate in the study and follow all study procedures.\n\nExclusion Criteria:\n\n* Infants with severe malnutrition.\n* Infants with major congenital anomalies other than biliary atresia.\n* Infants with positive tumor markers.","ALL","0 Days","90 Days",{"count":20,"type":21},14,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goal of this clinical trial with historical control is to evaluate whether umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy can improve clinical outcomes in infants with biliary atresia undergoing Kasai surgery before 90 days of age.\n\nThe main questions it aims to answer are:\n\nDoes UC-MSC therapy improve liver function parameters (bilirubin, albumin, liver enzymes, coagulation profile)? Does UC-MSC therapy reduce complications such as anemia, ascites, jaundice, and improve PELD scores? Does UC-MSC therapy improve overall survival compared to standard Kasai surgery alone? Researchers will compare the group receiving UC-MSC in 2025-2027 with a historical control group of patients who previously underwent Kasai surgery without UC-MSC therapy.\n\nParticipants will:\n\nUndergo preoperative evaluation, including laboratory and imaging tests. Receive Kasai surgery combined with intraoperative trans-portal vein injection of 20 million UC-MSCs.\n\nBe monitored postoperatively through serial laboratory tests, imaging (Fibroscan), and clinical assessments at scheduled intervals.\n\nBe followed up for potential serious adverse events and survival outcomes.",[27,28,29,30,31,32],"Biliary Atresia","Kasai Portoenterostomy","Mesenchymal Stem Cell Transplantation","Liver Function Disorders","Liver Fibrosis","Survival Rate","NOT_YET_RECRUITING","2025-05-30",{"date":36,"type":37},"2025-06-08","ACTUAL",{"date":39,"type":21},"2025-06-17",{"date":41,"type":21},"2026-04-17",{"name":43,"class":44},"Universitas Diponegoro","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100556485","early-phase-1-effect-of-hipec-after-radical-surgery-on-long-term-survival-for-locally-advanced-gastric-cancer-100556485","NCT06525714","Effect of HIPEC After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer","Effect of Prophylactic Hyperthermic Intraperitonal Chemotherapy（HIPEC）After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer（cT3N+M0 and cT4aN+\u002F-M0）: A Randomized-controlled Study","Inclusion Criteria:\n\n1. Age \\>18 and ≤70 years;\n2. Male or nonpregnant female;\n3. Gastric adenocarcinoma cT3N+M0 and cT4aN+\u002F-M0 (according to the 8th edition of the AJCC TNM staging system);\n4. No distant metastasis, suitable for D2 lymph node dissection;\n5. ECOG (Eastern Cooperative Oncology Group) performance status of 0-2;\n6. No prior cytotoxic chemotherapy, radiotherapy, or immunotherapy;\n7. Written informed consent given before any study-related procedures;\n\nExclusion Criteria:\n\n1. Other cancers within the past 5 years;\n2. Distant metastasis (M1) found during surgery;\n3. ASA (American Society of Anesthesiologists) classification ≥IV and\u002For ECOG performance status \\>2;\n4. Severe liver, kidney, cardiac, pulmonary, or coagulation dysfunction, or severe underlying diseases that make the patient unable to tolerate surgery;\n5. A history of severe mental illness;\n6. History of taking steroid medications;\n7. Receiving other chemotherapy, radiotherapy, or immunotherapy;\n8. Lack of written informed consent;",true,"18 Years","70 Years",{"count":57,"type":21},302,[59],"EARLY_PHASE1","The study focuses on patients with locally advanced gastric adenocarcinoma (cT3N+M0 and cT4aN+\u002F-M0), assessing the feasibility, surgical safety, and oncological benefit of prophylactic HIPEC treatment following laparoscopic D2 radical surgery.",[62,32],"Gastric Cancer","2024-07-29",{"date":65,"type":37},"2024-07-31",{"date":67,"type":21},"2024-08",{"date":69,"type":21},"2030-07",{"name":71,"class":44},"The First Hospital of Jilin University"]